Literature DB >> 6635912

Comparative study of parenteral piperacillin and cefoxitin in the treatment of surgical infections of the abdomen.

A Z Najem, Z C Kaminski, C R Spillert, E J Lazaro.   

Abstract

Patients who had contaminated traumatic perforations of the gastrointestinal tract and those with acute peritonitis resulting from acute surgical inflammatory conditions were treated with piperacillin or cefoxitin infused intravenously as single therapy for a minimum of five days. Thirty-four patients were given 4.5 grams of piperacillin every six hours and 26 patients, 2.0 grams of cefoxitin every six hours. In the piperacillin group, 63 organisms (34 aerobes and 29 anaerobes) were isolated from pretreatment cultures, while in the cefoxitin group, 73 organisms (35 aerobes and 38 anaerobes) were isolated. Clinical recovery was achieved in 31 of 34 patients receiving piperacillin therapy and in 24 of 26 patients receiving cefoxitin therapy. Organisms were found to be resistant to the respective drug in two piperacillin-treated patients and in one cefoxitin-treated patient, and the patients were given other antibacterial treatment. One patient from each treatment group died of causes unrelated to septic conditions. No serious adverse effects occurred from either antibiotic.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6635912

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  9 in total

1.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.

Authors:  G J Cuchural; F P Tally; N V Jacobus; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe; C Pierson
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

3.  Clinical comparison of piperacillin and cefoxitin in patients with bacteriologically confirmed infections.

Authors:  R V McCloskey
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

Review 4.  Role of aminoglycoside antibiotics in the treatment of intra-abdominal infection.

Authors:  J L Ho; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 5.  Piperacillin/tazobactam in the treatment of polymicrobial infections.

Authors:  S L Gorbach
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

6.  Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.

Authors:  D J Walters; J S Solomkin; J A Paladino
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

7.  Belgian Collaborative Study of the in-vitro susceptibility of the Bacteroides fragilis group. A Belgian Collaborative Study Group.

Authors: 
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

8.  Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.

Authors:  F P Tally; G J Cuchural; N V Jacobus; S L Gorbach; K Aldridge; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

Review 9.  Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; D M Richards; R N Brogden; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.